Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice
Open Access
- 28 October 2020
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 4S,p. 115-119
- https://doi.org/10.37489/2588-0519-2020-s4-115-119
Abstract
Global experience with the clinical use of favipiravir is very limited. Its safety is for further study. Prevention of teratogenic effects (mandatory pregnancy test before starting therapy, compliance with effective contraception by both women and men), control of the level of uric acid, transaminases and ECG are of fundamental importance. Alertness is needed for new, insufficiently documented or previously unreported adverse events such as motor disturbances and falls. Patients should be fully informed about all the risks of therapy before starting it. Special attention is required to timely fill out the approved forms of notifications on the development of HP and report them in time according to the Order of the Federal Service for Surveillance in Healthcare of February 15, 2017 No. 1071 «On approval of the Procedure for the implementation of pharmacovigilance.»Keywords
This publication has 9 references indexed in Scilit:
- A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19Antimicrobial Agents and Chemotherapy, 2020
- Neuroleptic malignant syndrome in patients with COVID-19The American Journal of Emergency Medicine, 2020
- Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019CEN Case Reports, 2020
- Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed DrugsClinical and Translational Science, 2020
- Drug repurposing approach to fight COVID-19Pharmacological Reports, 2020
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV InfectionClinical Pharmacology & Therapeutics, 2020
- Favipiravir, an anti-influenza drug against life-threatening RNA virus infectionsPharmacology & Therapeutics, 2020
- The effects of favipiravir on hematological parameters of covıd-19 patientsRevista da Associação Médica Brasileira, 2020
- Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adultsInternational journal of clinical pharmacology and therapeutics, 2015